[Form 4] Boston Scientific Corp. Insider Trading Activity

Rhea-AI Filing Summary

Kratos Defense & Security Solutions, Inc. (KTOS) insider Steven S. Fendley has filed a Form 144 notice to sell additional company stock.

• Proposed transaction: 7,000 common shares, estimated value $409,722.60, through Fidelity Brokerage Services on or after 28 Jul 2025.
• Share-base impact: The sale equals roughly 0.005% of the 152.84 million shares outstanding.
• Source of shares: Grant received 4 Jan 2024.
• Recent activity: Fendley has already sold 36,000 shares in the past three months, generating ~$1.33 million in gross proceeds.

The filer affirms no undisclosed adverse information and acknowledges Rule 10b5-1 liability. The filing signals continued insider liquidity but remains small relative to KTOS’s float.

Positive

• Sale size is immaterial at ~0.005% of total shares, limiting dilution or price impact.
• Transparent disclosure via Form 144 and affirmation of no undisclosed adverse information enhance governance clarity.

Negative

• Continued insider selling trend: 43,000 shares (current notice plus prior 36,000) in four months may unsettle some investors.

Insights

Securities Analyst

TL;DR: Small insider sale (0.005% float); follows recent 36k-share disposals—neutral signal given minor size vs. float.

The proposed 7,000-share Form 144 equates to roughly $410k and is immaterial against KTOS’s 152.8 M shares outstanding. Although Fendley has realized ~$1.33 M from 36k shares since April, the aggregate 43k shares represent just 0.03% of shares outstanding. Frequent but modest sales can indicate diversification rather than deteriorating fundamentals. No earnings or guidance data are affected, so I view the filing as neutral for valuation.

Corporate Governance Expert

TL;DR: Repetitive insider sales warrant monitoring, but size remains immaterial—governance risk low.

Fendley’s serial sales trigger scrutiny under governance best practices; however, the transactions are publicly disclosed, use a reputable broker, and represent a de minimis percentage of total equity. The certification of no undisclosed adverse information and potential 10b5-1 compliance mitigate suspicion of informational advantage. Overall impact on investor sentiment is limited, though continued patterns could raise questions if volumes escalate.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

LUDWIG EDWARD J

(Last) (First) (Middle)

300 BOSTON SCIENTIFIC WAY

(Street)

MARLBOROUGH MA 01752-1234

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BOSTON SCIENTIFIC CORP [ BSX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
07/25/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/25/2025		S		4,000	D	$106.0301	18,479	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Susan Thompson, Attorney-in-Fact	07/28/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many KTOS shares are being registered for sale in this Form 144?

The filing covers 7,000 common shares valued at approximately $409,723.

When is the planned sale date for the KTOS shares?

The approximate sale date disclosed is July 28, 2025.

What percentage of Kratos Defense’s outstanding shares does the sale represent?

Roughly 0.005% of the 152.84 million shares outstanding.

How many KTOS shares has Steven S. Fendley sold in the past three months?

He sold 36,000 shares between April and June 2025, generating about $1.33 million.

Does the Form 144 indicate any undisclosed negative information about KTOS?

No. The signer certifies that he is not aware of any material adverse information that has not been publicly disclosed.